What GLP-1 agonists actually do
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It signals satiety to the brain, slows gastric emptying, and improves insulin response. GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) — mimic this hormone at therapeutic doses.
The effects are not just appetite suppression. These medications appear to alter food reward signaling, reduce food preoccupation, and improve metabolic flexibility independent of caloric intake.[1]
What the major trials show
The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) are the largest randomized controlled trials in obesity medicine:
- STEP 1 (2021): 1,961 adults with BMI ≥30 — average body weight reduction of 14.9% at 68 weeks on semaglutide 2.4mg.[2]
- SURMOUNT-1 (2022): 2,539 adults with BMI ≥30 — average body weight reduction of 20.9% on tirzepatide 15mg at 72 weeks.[3]
- SELECT (2023): Semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and existing cardiovascular disease — outcomes that extend beyond weight loss alone.[4]
Who qualifies, who does not
Standard FDA labeling for chronic weight management requires a BMI ≥ 30, OR a BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea).
Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN-2), severe gastroparesis, and current pancreatitis. Pregnancy is also a contraindication. These are not optional considerations — they are reasons a particular individual should not be on the medication.
Why proper labs matter — before, during, and after
A responsible GLP-1 protocol includes baseline labs (HbA1c, fasting insulin, lipid panel, thyroid panel, liver and kidney function, and for some patients, calcitonin or thyroid imaging if there is family history). Periodic monitoring catches the rare but real adverse effects early — gallbladder issues, pancreatitis signals, thyroid changes — and tracks the metabolic improvements the medication is delivering.
It is also why these medications belong under physician supervision rather than direct-to-consumer distribution without clinical review. The "what dose at what tempo for which person" question is exactly what a physician evaluation answers.
The lifestyle question
The STEP and SURMOUNT trials all included lifestyle intervention alongside medication. The data is clear that GLP-1s plus structured lifestyle change produce significantly better outcomes than medication alone — and that lifestyle support helps preserve lean mass during weight loss.[5]
GLP-1s are not magic, but they are real. Used appropriately, monitored thoughtfully, and combined with the right supporting work, they represent one of the most impactful developments in obesity medicine in decades.
What to do with this information
If you have considered GLP-1 therapy, the right starting point is an honest clinical evaluation: do you meet eligibility criteria, what are your baseline labs, what is your full medical picture, and what supporting lifestyle work needs to happen alongside any medication. A physician consultation is the appropriate first step.
